Calculating occupancy when one does not have baseline: A comparison of different options

Journal of Cerebral Blood Flow and Metabolism

Volumn 31, Issue 8, 2011, Pages 1760-1767

  Kim, Euitae ^a,b,c   Howes, Oliver D ^b,c   Yu, Kyung Sang ^a   Jeong, Jae Min ^a   Lee, Jae Sung ^a   Jang, In Jin ^a   Shin, Sang Goo ^a   Kapur, Shitij ^c   Kwon, Jun Soo ^a  

^a Seoul National University   (South Korea)

^b MEDICAL RESEARCH COUNCIL   (United Kingdom)

^c KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

11C raclopride; Antipsychotic drug; dopamine receptor occupancy; positron emission tomography; schizophrenia; validation

Indexed keywords

ARIPIPRAZOLE; DOPAMINE 2 RECEPTOR; NEUROLEPTIC AGENT; RACLOPRIDE C 11; SEROTONIN 2A RECEPTOR; UNCLASSIFIED DRUG; YKP 1358;

ADULT; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATION COEFFICIENT; DRUG RECEPTOR BINDING; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PRIORITY JOURNAL; RECEPTOR AFFINITY; RECEPTOR OCCUPANCY; RELIABILITY; SCHIZOPHRENIA; SINGLE DRUG DOSE; VALIDATION STUDY;

ADULT; ALKALOIDS; ANTIPSYCHOTIC AGENTS; HUMANS; MALE; METHODS; PIPERAZINES; POSITRON-EMISSION TOMOGRAPHY; PROTEIN BINDING; QUINOLONES; RECEPTORS, DOPAMINE D2; REPRODUCIBILITY OF RESULTS; SCHIZOPHRENIA; YOUNG ADULT;

EID: 79960978687     PISSN: 0271678X     EISSN: 15597016     Source Type: Journal    
DOI: 10.1038/jcbfm.2011.54     Document Type: Article

References (33)

1. Alvan G, Paintaud G, Wakelkamp M (1999) The efficiency concept in pharmacodynamics. Clin Pharmacokinet 36:375-89 (Pubitemid 29261512)
2. Arakawa R, Ito H, Takano A, Takahashi H, Morimoto T, Sassa T, Ohta K, Kato M, Okubo Y, Suhara T (2008) Finding study of paliperidone ER based on striatal and extrastriatal dopamine D2 receptor occupancy in patients with schizophrenia. Psychopharmacology (Berl) 197:229-35
3. Danhof M, Mandema JW (1992) Modelling of the pharma-codynamics and pharmacodynamic interactions of CNS active drugs. Int J Clin Pharmacol Ther Toxicol 30:516-9 (Pubitemid 23001966)
4. Farde L, Nordstrom AL, Wiesel FA, Pauli S, Halldin C, Sedvall G (1992) Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. Arch Gen Psychiatry 49:538-44
5. Farde L, Wiesel FA, Stone-Elander S, Halldin C, Nordstrom AL, Hall H, Sedvall G (1990) D2 dopamine receptors in neuroleptic-naive schizophrenic patients. A positron emission tomography study with [11C]raclopride. Arch Gen Psychiatry 47:213-9 (Pubitemid 20086672)
6. Fischman AJ, Alpert NM, Rubin RH (2002) Pharmacoki-netic imaging: a noninvasive method for determining drug distribution and action. Clin Pharmacokinet 41:581-602 (Pubitemid 34848364)
7. Gefvert O, Bergstrom M, Langstrom B, Lundberg T, Lindstrom L, Yates R (1998) Time course of central nervous dopamine-D2 and 5-HT2 receptor blockade and plasma drug concentrations after discontinuation of quetiapine (Seroquel) in patients with schizophrenia. Psychopharmacology (Berl) 135:119-26 (Pubitemid 28055494)
8. Ginovart N, Wilson AA, Hussey D, Houle S, Kapur S (2009) D2-receptor upregulation is dependent upon temporal course of D2-occupancy: a longitudinal [11C]-raclopride PET study in cats. Neuropsychopharmacology 34: 662-71
9. Grunder G, Fellows C, Janouschek H, Veselinovic T, Boy C, Brocheler A, Kirschbaum KM, Hellmann S, Spreck-elmeyer KM, Hiemke C, Rosch F, Schaefer WM, Vernaleken I (2008) Brain and plasma pharmacokinetics of aripiprazole in patients with schizophrenia: an [18F]fallypride PET study. Am J Psychiatry 165: 988-95
10. Hirose T, Kikuchi T (2005) Aripiprazole, a novel anti-psychotic agent: dopamine D2 receptor partial agonist. J Med Invest 52(Suppl):284-90 (Pubitemid 43051889)
11. Ito H, Hietala J, Blomqvist G, Halldin C, Farde L (1998) Comparison of the transient equilibrium and continuous infusion method for quantitative PET analysis of [11C]raclopride binding. J Cereb Blood Flow Metab 18:941-50
12. Kapur S, Zipursky R, Jones C, Remington G, Houle S (2000) Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. Am J Psychiatry 157:514-20 (Pubitemid 30191189)
13. Kapur S, Zipursky RB, Remington G (1999) Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. Am J Psychiatry 156:286-93 (Pubitemid 29077120)
14. Kegeles LS, Abi-Dargham A, Frankle WG, Gil R, Cooper TB, Slifstein M, Hwang DR, Huang Y, Haber SN, Laruelle M (2010) Increased synaptic dopamine function in associative regions of the striatum in schizophrenia. Arch Gen Psychiatry 67:231-9
15. Kestler LP, Walker E, Vega EM (2001) Dopamine receptors in the brains of schizophrenia patients: a meta-analysis of the findings. Behav Pharmacol 12:355-71 (Pubitemid 32983509)
16. Lammertsma AA, Hume SP (1996) Simplified reference tissue model for PET receptor studies. Neuroimage 4: 153-8
17. Landis JR, Koch GG (1977) The measurement of observer agreement for categorical data. Biometrics 33:159-74 (Pubitemid 8054849)
18. Laruelle M (1998) Imaging dopamine transmission in schizophrenia. A review and meta-analysis. Q J Nucl Med 42:211-21 (Pubitemid 28529874)
19. Lee T, Seeman P, Tourtellotte WW, Farley IJ, Hornykeiwicz O (1978) Binding of 3H-neuroleptics and 3H-apomorphine in schizophrenic brains. Nature 274:897-900 (Pubitemid 9004058)
20. Lim KS, Kwon JS, Jang IJ, Jeong JM, Lee JS, Kim HW, Kang WJ, Kim JR, Cho JY, Kim E, Yoo SY, Shin SG, Yu KS (2007) Modeling of brain D2 receptor occupancy-plasma concentration relationships with a novel antipsychotic, YKP1358, using serial PET scans in healthy volunteers. Clin Pharmacol Ther 81:252-8 (Pubitemid 46174822)
21. Mackay AV, Iversen LL, Rossor M, Spokes E, Bird E, Arregui A, Creese I, Synder SH (1982) Increased brain dopamine and dopamine receptors in schizophrenia. Arch Gen Psychiatry 39:991-7 (Pubitemid 12020980)
22. Mamo D, Kapur S, Shammi CM, Papatheodorou G, Mann S, Therrien F, Remington G (2004) A PET study of dopamine D2 and serotonin 5-HT2 receptor occupancy in patients with schizophrenia treated with therapeutic doses of ziprasidone. Am J Psychiatry 161: 818-25 (Pubitemid 38625334)
23. McGuire P, Howes OD, Stone J, Fusar-Poli P (2008) Functional neuroimaging in schizophrenia: diagnosis and drug discovery. Trends Pharmacol Sci 29:91-8
24. Meibohm B, Derendorf H (1997) Basic concepts of pharmacokinetic/ pharmacodynamic (PK/PD) modelling. Int J Clin Pharmacol Ther 35:401-13 (Pubitemid 27462583)
25. Olsson H, Farde L (2001) Potentials and pitfalls using high affinity radioligands in PET and SPET determinations on regional drug induced D2 receptor occupancy-a simulation study based on experimental data. Neuro-image 14:936-45 (Pubitemid 32929894)
26. Pien HH, Fischman AJ, Thrall JH, Sorensen AG (2005) Using imaging biomarkers to accelerate drug development and clinical trials. Drug Discov Today 10:259-66 (Pubitemid 40222219)
27. Remington G, Mamo D, Labelle A, Reiss J, Shammi C, Mannaert E, Mann S, Kapur S (2006) A PET study evaluating dopamine D2 receptor occupancy for long-acting injectable risperidone. Am J Psychiatry 163: 396-401 (Pubitemid 44469380)
28. Shrout PE, Fleiss JL (1979) Intraclass correlations: uses in assessing rater reliability. Psychol Bull 86:420-8
29. Silvestri S, Seeman MV, Negrete J-C, Houle S, Shammi CM, Remington GJ, Kapur S, Zipursky RB, Wilson AA, Christensen BK, Seeman P (2000) Increased dopamine D 2 receptor binding after long-term treatment with antipsychotics in humans: a clinical PET study. Psy-chopharmacology 152:174-80
30. Tauscher J, Jones C, Remington G, Zipursky RB, Kapur S (2002) Significant dissociation of brain and plasma kinetics with antipsychotics. Mol Psychiatry 7:317-21 (Pubitemid 34280640)
31. Willmann JK, Van Bruggen N, Dinkelborg LM, Gambhir SS (2008) Molecular imaging in drug development. Nat Rev Drug Discov 7:591-607 (Pubitemid 351927724)
32. Wong DF, Wagner Jr HN, Tune LE, Dannals RF, Pearlson GD, Links JM, Tamminga CA, Broussolle EP, Ravert HT, Wilson AA, Toung JK, Malat J, Williams JA, O'Tuama LA, Snyder SH, Kuhar MJ, Gjedde A (1986) Positron emission tomography reveals elevated D2 dopamine receptors in drug-naive schizophrenics. Science 234:1558-63 (Pubitemid 17125279)
33. Yokoi F, Grunder G, Biziere K, Stephane M, Dogan , Dannals RF, Ravert H, Suri A, Bramer S, Wong DF (2002) Dopamine D2 and D3 receptor occupancy in normal humans treated with the antipsychotic drug aripipra-zole (OPC 14597): a study using positron emission tomography and [11C]raclopride. Neuropsychopharma-cology 27:248-59 (Pubitemid 34692591)